Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

C3 Ventures

Founders Benjamin McCann Erik Buchanan John Jersin

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 16
Average round size
info
The average size of a deal this fund participated in
$2M
Portfolio companies 13
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.12
Key employees 2
Stages of investment
Early Stage Venture
Seed

Areas of investment

  • Health Care
  • Software
  • Advanced Materials
  • Information Technology
  • Clinical Trials

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of C3 Ventures:
Typical Co-investors
C3 Ventures is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after C3 Ventures:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Adurance Venture -
Brandless California, San Francisco, United States
Century Securities China, Guangdong, Shenzhen
Danish Investment Fund for Developing Countries -
Dazi Huashi Chuangye Touzi Chengguan District, China, Lhasa
Difference Capital Canada, Ontario, Toronto
HI Cisco -
Inventec Corporation Taipei, Taiwan
JJ Capital Beijing, Beijing, China
LYVC California, San Mateo, United States
OK Group -
Propel Capital New York, New York, United States
Qidi Yinxing Beijing, China, Haidian
Quaker Capital Investments, LLC -
Reaction Fund California, Palo Alto, United States
Rural Electrification Agency Central Region, Kampala, Uganda
Treehouse Investments New York, New York, United States
Yantai Yuanjin Investment China, Jinan, Shandong
Yonghua Capital China, Shanghai, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

TômTex Co

Advanced Materials
Biotechnology
Sustainability
$1M15 Jan 2022 New York, New York, United States

VenoStent

Advanced Materials
Health Care
Medical Device
$3M23 Feb 2021 Nashville, Tennessee, United States

Cyberdontics

Dental
Health Care
$2M27 Jul 2020 Castlegar, British Columbia, Canada

AIRx Health

Health Care
Information Technology
Virtual Assistant
Wellness
22 Mar 2019 Cupertino, California, United States

Momentus

Aerospace
Space Travel
Transportation
$8M14 Nov 2018 San Jose, California, United States

UBITS

Corporate Training
E-Learning
EdTech
Education
Human Resources
$2M25 Oct 2018 Buenaventura, Valle del Cauca, Colombia

Curebase

Clinical Trials
Health Care
Software
$2M19 Oct 2018 San Francisco, California, United States

FREY

Brand Marketing
Consumer Goods
Fashion
Laundry and Dry-cleaning
Men's
$2M28 Sep 2018 San Francisco, California, United States

Shone

Artificial Intelligence
Marine Transportation
Transportation
$4M26 Jun 2018 San Francisco, California, United States
News
VenoStent Raises $2.3M Seed Funding

– VenoStent, an advanced materials company, today announced $2.3 million in seed funding.
– The company leverages its unique polymer engineering technology to develop bioresorbable slip-on polymer wraps, called SelfWrap.
– The product is aimed to eliminate vascular surgery failures, at first targeting vascular access surgery required to initiate hemodialysis treatment for end-stage renal disease (ESRD) patients.
Creative Ventures led the round with participation from IAG Capital Partners, C3 Ventures, Olima Ventures, Texas Halo Fund, Cowtown Angels, and SP Investment Fund, among other prominent investors.
– This brings the total funding to date to more than $6 million.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent C3 Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 16
Average round size 2M
Peak activity year 2018
Lead investments 0
Follow on index 0.12
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

TômTex Co

Advanced Materials
Biotechnology
Sustainability
$1M15 Jan 2022 New York, New York, United States

VenoStent

Advanced Materials
Health Care
Medical Device
$3M23 Feb 2021 Nashville, Tennessee, United States

Cyberdontics

Dental
Health Care
$2M27 Jul 2020 Castlegar, British Columbia, Canada

AIRx Health

Health Care
Information Technology
Virtual Assistant
Wellness
22 Mar 2019 Cupertino, California, United States

Momentus

Aerospace
Space Travel
Transportation
$8M14 Nov 2018 San Jose, California, United States

UBITS

Corporate Training
E-Learning
EdTech
Education
Human Resources
$2M25 Oct 2018 Buenaventura, Valle del Cauca, Colombia

Curebase

Clinical Trials
Health Care
Software
$2M19 Oct 2018 San Francisco, California, United States

FREY

Brand Marketing
Consumer Goods
Fashion
Laundry and Dry-cleaning
Men's
$2M28 Sep 2018 San Francisco, California, United States

Shone

Artificial Intelligence
Marine Transportation
Transportation
$4M26 Jun 2018 San Francisco, California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: